Thu, May 15, 8:42 PM (59 days ago)
**Quarta-Rad, Inc. (QURT:OTC) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** Total sales increased by 49.20% to $32,887 (up from $22,042 in Q1 2024), driven by Sellavir's revenue of $30,000. - **Profit Margins:** Quarta-Rad reported a gross loss of $1,360, while Sellavir had a gross loss of $1,898. - **Cash Flow:** Net cash used in operating activities was $13,267, a decrease from $22,557 in Q1 2024. - **Earnings Changes:** Net loss decreased by 15.54% to $77,409 (from $91,651 in Q1 2024). **Segment Performance:** - **Quarta-Rad:** Revenue dropped by 86.90% to $2,887, with a net loss increase of 10.97% to $41,240. - **Sellavir:** Revenue increased to $30,000, with a net loss decrease of 10.70% to $36,169. **Trends & Uncertainties:** - **Geopolitical Risks:** Supply chain disruptions due to the Russian invasion of Ukraine and EU restrictions. - **Operational Focus:** Shift towards AI-driven call center software (CenterEye) and away from radiation detection devices. - **Financial Concerns:** Recurring operating losses and substantial doubt about the ability to continue as a going concern. **Future Operations Impact:** - **Inventory:** Plans to purchase inventory to boost sales. - **Software Development:** Continued investment in CenterEye. - **Marketing:** Increased efforts to generate leads and sales, with an estimated cost of $25,000-$75,000. - **Partnerships:** Aim to establish partnerships with call center operators and technology resellers. **Management's Plan:** - Maintain adequate working capital and adhere to prudent financial forecasting. - Explore plans to distribute current operations and support new service lines. - No plans to hire additional employees or make significant capital expenditures in the near term. **Internal Controls:** - Material weaknesses identified in internal controls over financial reporting. - Plans to remediate deficiencies as resources become available.